* Applied DNA Systems Inc., of Warwick, R.I., has registered withthe Securities and Exchange Commission to sell 700,000 shares ofcommon stock. The public offering will be underwritten by StarrSecurities. Applied DNA is a subsidiary of Analytical BiosystemsCorp., also of Warwick, R.I.* Therion Biologics Corp., of Cambridge, Mass., has signed a five-year collaborative research and development agreement with theNational Cancer Institute (NCI) to develop cancer vaccines.Therion's research involves creating vaccines based on liveswinepox and vaccinia viruses that express genes encoding tumor-associated antigens, cytokines and T cell co-stimulatory factors.Under the agreement, NCI will supply Therion with the genes.* Hycor Biomedical Inc., of Irvine Calif., has paid $2 million toacquire Medical Specialties International Inc., of South Plainfield,N.J. The purchase agreement included 200,000 shares of Hycorstock, plus additional payments based on performance.* Mycogen Corp., of San Diego, has applied with theEnvironmental Protection Agency for approval to marketgenetically engineered corn seeds which are resistant to insectdamage. The hybrid seeds produce a protein that is designed toprotect against European corn borers.* Xenometrix Inc., of Boulder, Colo., has licensed tests based on itsstress gene assay and genotoxicity assay systems to Funakoshi Ltd.,of Tokyo, for marketing in Japan. Xenometrix retains worldwidemarketing rights outside Japan.* Epigen Inc., of Wellesley, Mass., said the American StockExchange halted trading of the company Sept. 28. on the EmergingCompany Marketplace. Epigen said it is seeking a private stockplacement of between $1.2 million and $7 million in an effort toresume trading on the AMEX.* Parcelsian Inc., of Ithaca, N.Y., has signed an agreement withIdexx Laboratories Corp., of Westport, Maine, to develop a cancertest for animals.* Medarex Inc., of Annandale, N.J., said its MDX-210 bispecificantibody therapy for treatment of prostate cancer will be evaluatedin a clinical trial conducted by researchers at Dartmouth UniversityMedical School, in Hanover, N.H. The study is being funded by theAssociation for the Cure of Cancer of the Prostate.* CSL Ltd., of Victoria, Australia, has acquired a majority interestin Sweden-based Iscotec AB, a research and development companyspecializing in vaccine adjuvants. CSL is expected to launch clinicaltrials of an Iscotec-developed adjuvanted influenza vaccine in early1995.* Ribi ImmunoChem Research Inc., of Hamilton, Mont., andSmithKline Beecham Corp., of Philadelphia, reported that Phase IItrials of the former's MPL immunomodulator, a vaccine adjuvant,enhanced the affect of SmithKline's genital herpes vaccine in astudy of 80 patients. A Phase III trial of the herpes vaccine withMPL is expected to begin this month. Vaccines will be given touninfected people who are in steady sexual relationships withinfected partners.
(c) 1997 American Health Consultants. All rights reserved.